Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Avantor raises FY revenue growth, profit guidance after Q3 beat

By Reuters News


Overview

  • US life science tools firm's Q3 sales rose 4.6%, beating analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company raised FY 2026 guidance for organic revenue growth, adjusted EPS and free cash flow


Outlook

  • Avantor raises FY 2026 organic revenue growth outlook to +0.75% to +1.25% from -0.5% to +0.5%

  • Company lifts FY 2026 adjusted EPS guidance to $0.81-$0.83 from $0.80-$0.83

  • Avantor increases FY 2026 free cash flow forecast to $525 mln-$550 mln from $500 mln-$550 mln


Result Drivers

  • SEGMENT PERFORMANCE - VWR Distribution & Services delivered improved revenue performance with organic growth accelerating to 5.8%, while Bioscience & Medtech Products returned to organic growth as expected

  • EXECUTION IMPROVEMENTS - Co attributed results to sharpened strategic focus and improved execution


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.70 bln

$1.64 bln (15 Analysts)

Q3 Adjusted EPS

Beat

$0.22

$0.21 (16 Analysts)

Q3 Net Income

$203.40 mln

Q3 Gross Profit

$534.80 mln

Q3 Operating Income

$139.50 mln

Q3 Pretax Profit

$98 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 15 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Avantor, Inc. is $15.00, about 12.4% below its October 27 closing price of $17.13

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

  • Oct 27 - Repligen Q3 revenue beats estimates on higher demand; lifts outlook

  • Oct 27 - Nautilus Biotechnology Q3 revenue beats


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.